Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 46

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 46
---
 New Warrant Shares, are subject to adjustment in the event of any stock dividend or split,
reverse stock split, recapitalization, reorganization, or similar transaction, as described in the New Warrants. In addition, the New Warrants provide that we may also, at any time during the term of the New Warrants, subject to the prior written consent of the applicable holder, voluntarily reduce the then current exercise price to any amount and for any period of time, subject to the rules and regulations of Nasdaq.

A holder will not have the
right to exercise any portion of the New Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99%
(or, upon election of the holder, 9.99%) of the number of shares of our Common Stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the New Warrants. However, any holder may increase
or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

In the event of a Fundamental
Transaction (as such term is defined in the New Warrant), then the successor entity will succeed to, and be substituted for the Company,
and may exercise every right and power that the Company may exercise and will assume all of its obligations under the New Warrants with
the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given a choice as to
the securities, cash, or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as to the
consideration it receives upon any exercise of the New Warrants following such Fundamental Transaction. In addition, the successor entity,
at the request of holders of New Warrants, will be obligated to purchase any unexercised portion of the New Warrants in accordance with
the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the New Warrants have the
right to require the Company or a successor entity to redeem the New Warrants for cash in the amount of the Black Scholes Value (as defined
in the New Warrant) of the unexercised portion of the New Warrants concurrently with or within 30 days following the consummation of a
Fundamental Transaction. However, in the event of a Fundamental Transaction which is not in our control, including a Fundamental Transaction
not approved by